TAFRO syndrome is a rare human systemic disease. The name is formed from the initials of thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly. [1] [2] [3] It was first described, in three patients, in 2010 by Takei et al, [4] and was discussed at two meetings held in 2012. [5]
It has "significant overlap" with Castleman's disease but "[its] features warrant its classification as a separate subtype of idiopathic multicentric Castleman's disease (iMCD)". [3]
It was reported in 2025 that Anakinra had been used successfully in two cases of paediatric TAFRO syndrome. [6]
{{cite journal}}
: CS1 maint: DOI inactive as of July 2025 (link)